



Market Announcement

4 April 2023

Cynata Therapeutics Limited (ASX: CYP) – Trading Halt

Description

The securities of Cynata Therapeutics Limited ('CYP') will be placed in trading halt at the request of CYP, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 6 April 2023 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Adviser, Listings Compliance

ASX ANNOUNCEMENT

4 April 2023

ASX Compliance
Level 50, South Tower
Rialto, 525 Collins Street
Melbourne VIC 3000

By email: tradinghaltsmelbourne@asx.com.au

Request for Trading Halt

Cynata Therapeutics Limited (“**Cynata**” or “the **Company**”) (ASX:CYP) requests that its securities be placed into an immediate trading halt.

In accordance with Listing Rule 17.1, the Company advises:

- (a) the trading halt is requested pending an announcement by the Company in relation to a proposed capital raising, to be undertaken by way of an institutional share placement and share purchase plan;
- (b) the Company requests that the trading halt remain in place until the earlier of the Company making an announcement in relation to the capital raising and the opening of trading on Thursday, 6 April 2023;
- (c) the Company is not aware of any reason why the trading halt should not be granted; and
- (d) the Company is not aware of any other information necessary to inform the market about the trading halt.

-ENDS-

Authorised for release by the Board of Directors

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343, ross.macdonald@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD under a cleared US FDA IND is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.